Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.

The chemokine system represents a diverse group of G protein-coupled receptors responsible for orchestrating cell recruitment under both homeostatic and inflammatory conditions. Chemokine receptor 9 (CCR9) is a chemokine receptor known to be central for migration of immune cells into the intestine....

Bibliografske podrobnosti
Main Authors:	Walters, M, Wang, Y, Lai, N, Baumgart, T, Zhao, B, Dairaghi, D, Bekker, P, Ertl, L, Penfold, M, Jaen, J, Keshav, S, Wendt, E, Pennell, A, Ungashe, S, Wei, Z, Wright, J, Schall, T
Format:	Journal article
Jezik:	English
Izdano:	2010

Podobne knjige/članki

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
od: Ungashe, S, et al.
Izdano: (2008)

Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
od: Bekker, P, et al.
Izdano: (2007)

Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
od: Keshav, S, et al.
Izdano: (2007)

PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
od: Bekker, P, et al.
Izdano: (2009)

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
od: Keshav, S, et al.
Izdano: (2009)

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
od: Satish Keshav, et al.
Izdano: (2013-01-01)

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
od: Keshav, S, et al.
Izdano: (2007)

Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis
od: Wei, Z, et al.
Izdano: (2005)

Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease
od: Bekker, P, et al.
Izdano: (2007)

Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
od: Bekker, P, et al.
Izdano: (2008)

CCR9 Antagonists in the Treatment of Ulcerative Colitis
od: Pirow Bekker, et al.
Izdano: (2015-01-01)

Antagonist of chemokine receptors CCR1 and CCR3
od: Ammit Alaina, et al.
Izdano: (2000-11-01)

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
od: Pirow Bekker, et al.
Izdano: (2016-01-01)

Abduction of chemokine elements by herpesviruses
od: Dairaghi, D, et al.
Izdano: (1998)

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
od: Pirow Bekker, et al.
Izdano: (2019-01-01)

Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
od: Bekker, P, et al.
Izdano: (2008)

Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease
od: Bekker, P, et al.
Izdano: (2008)

Expression of CCR8 and CCX-CKR on Basophils in Chronic Urticaria Is Amplified by IgE-Mediated Activation
od: Ewa A. Bartko, et al.
Izdano: (2023-05-01)

Screening of chemokine receptor CCR4 antagonists by capillary zone electrophoresis
od: Zhe Sun, et al.
Izdano: (2011-11-01)

CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.
od: Wendt, E, et al.
Izdano: (2015)

CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease
od: Wendt E, et al.
Izdano: (2015-04-01)

CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells.
od: Greaves, D, et al.
Izdano: (1997)

The GHS-R Blocker D-[Lys3] GHRP-6 Serves as CCR5 Chemokine Receptor Antagonist
od: Kalpesh Patel, Vishwa Deep Dixit, Jun Ho Lee, Jie Wan Kim, Eric M. Schaffer, Dzung Nguyen, Dennis D. Taub
Izdano: (2012-01-01)

Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5
od: Hui Zhang, et al.
Izdano: (2021-07-01)

A systemically-administered small molecule antagonist of CCR9 acts as a tissue-selective inhibitor of lymphocyte trafficking.
od: Noah J Tubo, et al.
Izdano: (2012-01-01)

Therapeutic Effect of C-C Chemokine Receptor Type 1 (CCR1) Antagonist BX471 on Allergic Rhinitis
od: Feng S, et al.
Izdano: (2020-07-01)

Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice.
od: Rodrigo Guabiraba, et al.
Izdano: (2010-01-01)

The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice.
od: Feng Liang, et al.
Izdano: (2018-01-01)

Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3
od: Zhehua Shao, et al.
Izdano: (2022-05-01)

Identification and Expression Profiling Analysis of the Cation/Ca2+ Exchanger (CCX) Gene Family: Overexpression of SlCCX1-LIKE Regulates the Leaf Senescence in Tomato Flowering Phase
od: Jiao Li, et al.
Izdano: (2021-06-01)

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.
od: Kathleen M C Sullivan, et al.
Izdano: (2023-01-01)

Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial
od: Mark Jones, et al.
Izdano: (2024-10-01)

The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis.
od: Maximilian Larena, et al.
Izdano: (2012-01-01)

Expression and function of the chemokine receptor CCR7 in thyroid carcinomas.
od: Sancho, M, et al.
Izdano: (2006)

Non-redundant roles of the CCR1 and CCR2 chemokine axes in monocyte recruitment during lung metastasis
od: Alessia G. Liner, et al.
Izdano: (2025-01-01)

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
od: Daniel Clark Files, et al.
Izdano: (2022-06-01)

The chemokine receptor CCR5: multi-faceted hook for HIV-1
od: Natacha Faivre, et al.
Izdano: (2024-01-01)

In Silico Identification of Cholesterol Binding Motifs in the Chemokine Receptor CCR3
od: Evan van Aalst, et al.
Izdano: (2021-07-01)

Structural basis of dimerization of chemokine receptors CCR5 and CXCR4
od: Daniele Di Marino, et al.
Izdano: (2023-10-01)

Chemokine receptor CCR3 is important for migration of mast cells in neurofibroma
od: Wei-Chun Tai, et al.
Izdano: (2010-12-01)